Relation between red cell distribution width and fibroblast growth factor 23 cleaving in patients with chronic kidney disease and heart failure

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Van Breda, Fenna ^a   Emans, Mireille E ^b   Van Der Putten, Karien ^c   Braam, Branko ^d   Van Ittersum, Frans J ^a   Kraaijenhagen, Rob J ^e   De Borst, Martin H ^f   Vervloet, Marc ^a   Gaillard, Carlo A J M ^f  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b IKAZIA HOSPITAL   (Netherlands)

^c TERGOOI HOSPITAL   (Netherlands)

^d UNIVERSITY OF ALBERTA   (Canada)

^e MEANDER MEDICAL CENTER   (Netherlands)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; FIBROBLAST GROWTH FACTOR;

ADVERSE OUTCOME; AGED; ANEMIA; ARTICLE; CARBOXY TERMINAL SEQUENCE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CATABOLISM; CHRONIC KIDNEY DISEASE; ERYTHROCYTE PARAMETERS; FEMALE; HEART FAILURE; HUMAN; INFLAMMATION; IRON METABOLISM; KIDNEY FUNCTION; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PHOSPHATE METABOLISM; PROTEIN DEGRADATION; RED CELL DISTRIBUTION WIDTH; BLOOD; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COMPLICATION; CROSS-SECTIONAL STUDY; MEAN CORPUSCULAR VOLUME; METABOLISM; MULTIVARIATE ANALYSIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CROSS-SECTIONAL STUDIES; ERYTHROCYTE INDICES; FEMALE; FIBROBLAST GROWTH FACTORS; HEART FAILURE; HUMANS; MALE; MULTIVARIATE ANALYSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84937846339     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0128994     Document Type: Article

References (37)

1. Scrutinio D, Passantino A, Santoro D, Catanzaro R (2011) The cardiorenal anaemia syndrome in systolic heart failure: prevalence, clinical correlates, and long-term survival. Eur J Heart Fail 13: 61-67. hfq167 [pii];doi: 10.1093/eurjhf/hfq167 PMID: 20858705
2. Smith GL, Lichtman JH, Bracken MB, Shlipak MG, Phillips CO, DiCapua P, Krumholz HM (2006) Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol 47: 1987-1996. S0735-1097(06)00488-8 [pii];doi: 10.1016/j.jacc.2005.11.084 PMID: 16697315
3. Shlipak MG, Fried LF, Cushman M, Manolio TA, Peterson D, Stehman-Breen C, Bleyer A, Newman A, Siscovick D, Psaty B (2005) Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA 293: 1737-1745. 293/14/1737 [pii];doi: 10.1001/jama.293.14. 1737 PMID: 15827312
4. Lippi G, Targher G, Montagnana M, Salvagno GL, Zoppini G, Guidi GC (2008) Relationship between red blood cell distribution width and kidney function tests in a large cohort of unselected outpatients. Scand J Clin Lab Invest 68: 745-748. 794905563 [pii];doi: 10.1080/00365510802213550 PMID: 18618369
5. Zoccali C, Yilmaz MI, Mallamaci F (2013) FGF23: A Mature Renal and Cardiovascular Risk Factor? Blood Purif 36: 52-57. 000351001 [pii];doi: 10.1159/000351001 PMID: 23735695
6. Farrow EG, Yu X, Summers LJ, Davis SI, Fleet JC, Allen MR, Robling AG, Stayrook KR, Jideonwo V, Magers MJ, Garringer HJ, Vidal R, Chan RJ, Goodwin CB, Hui SL, Peacock M, White KE (2011) Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci U S A 108: E1146-E1155. 1110905108 [pii];doi: 10.1073/pnas.1110905108 PMID: 22006328
7. Wolf M, Koch TA, Bregman DB (2013) Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res. doi: 10.1002/jbmr.1923
8. Bournier M, Tissot N, Mari S, Boucherez J, Lacombe E, Briat JF, Gaymard F (2013) Arabidopsis ferritin 1 (AtFer1) gene regulation by the phosphate starvation response 1 (AtPHR1) transcription factor reveals a direct molecular link between iron and phosphate homeostasis. J Biol Chem 288: 22670- 22680. M113.482281 [pii];doi: 10.1074/jbc.M113.482281 PMID: 23788639
9. Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, Ritz E, Kronenberg F, Kuen E, Konig P, Kraatz G, Mann JF, Muller GA, Kohler H, Riegler P (2007) Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 18: 2600-2608. ASN.2006080936 [pii];doi: 10.1681/ASN.2006080936 PMID: 17656479
10. Hsu HJ, Wu MS (2009) Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients. Am J Med Sci 337: 116-122. doi: 10.1097/MAJ.0b013e3181815498 ;00000441-200902000-00009 [pii]. PMID: 19214027
11. Gutierrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, Hoffmann U, Coglianese E, Christenson R, Wang TJ, deFilippi C, Wolf M (2009) Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 119: 2545-2552. CIRCULATIONAHA.108.844506 [pii];doi: 10.1161/CIRCULATIONAHA.108.844506 PMID: 19414634
12. Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Juppner H, Wolf M (2008) Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359: 584-592. 359/6/584 [pii];doi: 10.1056/NEJMoa0706130 PMID: 18687639
13. Jean G, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, Chazot C (2009) High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant 24: 2792-2796. gfp191 [pii];doi: 10.1093/ndt/gfp191 PMID: 19395730
14. Baia LC, Humalda JK, Vervloet MG, Navis G, Bakker SJ, de Borst MH (2013) Fibroblast growth factor 23 and cardiovascular mortality after kidney transplantation. Clin J Am Soc Nephrol 8: 1968-1978. CJN.01880213 [pii];doi: 10.2215/CJN.01880213 PMID: 23929933
15. Wolf M, White KE (2014) Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease. Curr Opin Nephrol Hypertens 23: 411-419. doi: 10.1097/01.mnh. 0000447020.74593.6f PMID: 24867675
16. Felker GM, Allen LA, Pocock SJ, Shaw LK, McMurray JJ, Pfeffer MA, Swedberg K, Wang D, Yusuf S, Michelson EL, Granger CB (2007) Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. J Am Coll Cardiol 50: 40-47. S0735- 1097(07)01270-3 [pii];doi: 10.1016/j.jacc.2007.02.067 PMID: 17601544
17. Forhecz Z, Gombos T, Borgulya G, Pozsonyi Z, Prohaszka Z, Janoskuti L (2009) Red cell distribution width in heart failure: prediction of clinical events and relationship with markers of ineffective erythropoiesis, inflammation, renal function, and nutritional state. Am Heart J 158: 659-666. S0002-8703(09) 00551-1 [pii];doi: 10.1016/j.ahj.2009.07.024 PMID: 19781428
18. Pascual-Figal DA, Bonaque JC, Redondo B, Caro C, Manzano-Fernandez S, Sanchez-Mas J, Garrido IP, Valdes M (2009) Red blood cell distribution width predicts long-term outcome regardless of anaemia status in acute heart failure patients. Eur J Heart Fail 11: 840-846. hfp109 [pii];doi: 10.1093/eurjhf/ hfp109 PMID: 19696056
19. Allen LA, Felker GM, Mehra MR, Chiong JR, Dunlap SH, Ghali JK, Lenihan DJ, Oren RM, Wagoner LE, Schwartz TA, Adams KF Jr. (2010) Validation and potential mechanisms of red cell distribution width as a prognostic marker in heart failure. J Card Fail 16: 230-238. S1071-9164(09)01176-2 [pii];doi: 10. 1016/j.cardfail.2009.11.003 PMID: 20206898
20. Tonelli M, Sacks F, Arnold M, Moye L, Davis B, Pfeffer M (2008) Relation Between Red Blood Cell Distribution Width and Cardiovascular Event Rate in People With Coronary Disease. Circulation 117: 163-168. CIRCULATIONAHA.107.727545 [pii];doi: 10.1161/CIRCULATIONAHA.107.727545 PMID: 18172029
21. Oh HJ, Park JT, Kim JK, Yoo DE, Kim SJ, Han SH, Kang SW, Choi KH, Yoo TH (2012) Red blood cell distribution width is an independent predictor of mortality in acute kidney injury patients treated with continuous renal replacement therapy. Nephrol Dial Transplant 27: 589-594. gfr307 [pii];doi: 10.1093/ ndt/gfr307 PMID: 21712489
22. Patel KV, Ferrucci L, Ershler WB, Longo DL, Guralnik JM (2009) Red blood cell distribution width and the risk of death in middle-aged and older adults. Arch Intern Med 169: 515-523. 169/5/515 [pii];doi: 10.1001/archinternmed.2009.11 PMID: 19273783
23. Patel KV, Semba RD, Ferrucci L, Newman AB, Fried LP, Wallace RB, Bandinelli S, Phillips CS, Yu B, Connelly S, Shlipak MG, Chaves PH, Launer LJ, Ershler WB, Harris TB, Longo DL, Guralnik JM (2010) Red cell distribution width and mortality in older adults: a meta-analysis. J Gerontol A Biol Sci Med Sci 65: 258-265. glp163 [pii];doi: 10.1093/gerona/glp163 PMID: 19880817
24. Perlstein TS, Weuve J, Pfeffer MA, Beckman JA (2009) Red blood cell distribution width and mortality risk in a community-based prospective cohort. Arch Intern Med 169: 588-594. 169/6/588 [pii];doi: 10. 1001/archinternmed.2009.55 PMID: 19307522
25. Emans ME, van der Putten K, van Rooijen KL, Kraaijenhagen RJ, Swinkels D, van Solinge WW, Cramer MJ, Doevendans PA, Braam B, Gaillard CA (2011) Determinants of red cell distribution width (RDW) in cardiorenal patients: RDW is not related to erythropoietin resistance. J Card Fail 17: 626-633. S1071-9164(11)00153-9 [pii];doi: 10.1016/j.cardfail.2011.04.009 PMID: 21807323
26. van der Putten K, Jie KE, Emans ME, Verhaar MC, Joles JA, Cramer MJ, Velthuis BK, Meiss L, Kraaijenhagen RJ, Doevendans PA, Braam B, Gaillard CA (2010) Erythropoietin treatment in patients with combined heart and renal failure: objectives and design of the EPOCARES study. J Nephrol 23: 363-368. 59A56384-BA5A-41AD-91C7-179279C019CD [pii]. PMID: 20383871
27. Wish JB (2006) Assessing iron status: beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol 1 Suppl 1: S4-S8. 1/Supplement-1/S4 [pii];doi: 10.2215/CJN.01490506
28. Heijboer AC, Levitus M, Vervloet MG, Lips P, ter Wee PM, Dijstelbloem HM, Blankenstein MA (2009) Determination of fibroblast growth factor 23. Ann Clin Biochem 46: 338-340. acb.2009.009066 [pii]; doi: 10.1258/acb.2009.009066 PMID: 19564163
29. Vervloet MG, van Zuilen AD, Heijboer AC, ter Wee PM, Bots ML, Blankestijn PJ, Wetzels JF (2012) Fibroblast growth factor 23 is associated with proteinuria and smoking in chronic kidney disease: an analysis of the MASTERPLAN cohort. BMC Nephrol 13: 20. 1471-2369-13-20 [pii];doi: 10.1186/1471- 2369-13-20 PMID: 22530966
30. Wolf M (2012) Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int 82: 737-747. ki2012176 [pii];doi: 10.1038/ki.2012.176 PMID: 22622492
31. Mirza MA, Alsio J, Hammarstedt A, Erben RG, Michaelsson K, Tivesten A, Marsell R, Orwoll E, Karlsson MK, Ljunggren O, Mellstrom D, Lind L, Ohlsson C, Larsson TE (2011) Circulating fibroblast growth factor-23 is associated with fat mass and dyslipidemia in two independent cohorts of elderly individuals. Arterioscler Thromb Vasc Biol 31: 219-227. ATVBAHA.110.214619 [pii];doi: 10.1161/ATVBAHA.110. 214619 PMID: 20966399
32. Munoz MJ, Isakova T, Ricardo AC, Xie H, Navaneethan SD, Anderson AH, Bazzano LA, Xie D, Kretzler M, Nessel L, Hamm LL, Negrea L, Leonard MB, Raj D, Wolf M (2012) Fibroblast growth factor 23 and Inflammation in CKD. Clin J Am Soc Nephrol 7: 1155-1162. CJN.13281211 [pii];doi: 10.2215/CJN. 13281211 PMID: 22554719
33. Lippi G, Targher G, Montagnana M, Salvagno GL, Zoppini G, Guidi GC (2009) Relation between red blood cell distribution width and inflammatory biomarkers in a large cohort of unselected outpatients. Arch Pathol Lab Med 133: 628-632. 2008-0279-OAR1 [pii];doi: 10.1043/1543-2165-133.4.628 PMID: 19391664
34. Yilmaz MI, Sonmez A, Saglam M, Yaman H, Kilic S, Turker T, Unal HU, Gok M, Cetinkaya H, Eyileten T, Oguz Y, Caglar K, Vural A, Mallamaci F, Zoccali C (2013) Longitudinal analysis of vascular function and biomarkers of metabolic bone disorders before and after renal transplantation. Am J Nephrol 37: 126-134. 000346711 [pii];doi: 10.1159/000346711 PMID: 23391995
35. Yilmaz MI, Sonmez A, Saglam M, Yaman H, Kilic S, Demirkaya E, Eyileten T, Caglar K, Oguz Y, Vural A, Yenicesu M, Zoccali C (2010) FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease. Kidney Int 78: 679-685. ki2010194 [pii];doi: 10.1038/ki.2010.194 PMID: 20613714
36. Mirza MA, Larsson A, Lind L, Larsson TE (2009) Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis 205: 385-390. S0021-9150(09)00009-4 [pii];doi: 10.1016/j.atherosclerosis.2009.01.001 PMID: 19181315
37. Goetz R, Nakada Y, Hu MC, Kurosu H, Wang L, Nakatani T, Shi M, Eliseenkova AV, Razzaque MS, Moe OW, Kuro-o M, Mohammadi M (2010) Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation. Proc Natl Acad Sci U S A 107: 407-412. 0902006107 [pii];doi: 10.1073/pnas.0902006107 PMID: 19966287